IE921683A1 - Modulation of cellular response to external stimuli - Google Patents

Modulation of cellular response to external stimuli

Info

Publication number
IE921683A1
IE921683A1 IE168392A IE921683A IE921683A1 IE 921683 A1 IE921683 A1 IE 921683A1 IE 168392 A IE168392 A IE 168392A IE 921683 A IE921683 A IE 921683A IE 921683 A1 IE921683 A1 IE 921683A1
Authority
IE
Ireland
Prior art keywords
cells
eaid
cell
agent
amount
Prior art date
Application number
IE168392A
Other languages
English (en)
Inventor
James A Bianco
Stuart L Bursten
Jack W Singer
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of IE921683A1 publication Critical patent/IE921683A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IE168392A 1991-05-24 1992-07-01 Modulation of cellular response to external stimuli IE921683A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70499291A 1991-05-24 1991-05-24
US73222791A 1991-07-16 1991-07-16

Publications (1)

Publication Number Publication Date
IE921683A1 true IE921683A1 (en) 1992-12-02

Family

ID=27107424

Family Applications (1)

Application Number Title Priority Date Filing Date
IE168392A IE921683A1 (en) 1991-05-24 1992-07-01 Modulation of cellular response to external stimuli

Country Status (7)

Country Link
EP (2) EP0573617A1 (enExample)
JP (1) JP3566719B2 (enExample)
AU (1) AU664189B2 (enExample)
CA (1) CA2109796C (enExample)
IE (1) IE921683A1 (enExample)
IL (1) IL101982A (enExample)
WO (1) WO1992021344A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
CA2112239C (en) * 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US5580873A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds to treat proliferative vascular diseases
EP0728003A1 (en) 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
AU1990195A (en) * 1994-03-08 1995-09-25 Cell Therapeutics, Inc. Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
US5843943A (en) * 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
CA2208580A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
CA2335595A1 (en) * 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US20110059994A1 (en) * 2008-01-31 2011-03-10 Korea Institute Of Science And Technology Composition for preventing or treating brain cancers
JP2011510976A (ja) * 2008-01-31 2011-04-07 韓国科学技術研究院 イノシトール１，４，５−三リン酸受容体サブタイプ３の阻害用の組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
IL106861A (en) * 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
ES2093138T3 (es) * 1991-05-23 1996-12-16 Hoechst Ag El empleo de 1-(5-oxohexil)-3-metil-7-n-propil-xantina en cirugia vascular.

Also Published As

Publication number Publication date
EP0573617A4 (enExample) 1994-02-09
JP3566719B2 (ja) 2004-09-15
IL101982A0 (en) 1992-12-30
WO1992021344A3 (en) 1993-12-09
AU664189B2 (en) 1995-11-09
WO1992021344A2 (en) 1992-12-10
CA2109796A1 (en) 1992-12-10
EP1214938A2 (en) 2002-06-19
IL101982A (en) 2000-02-29
CA2109796C (en) 2004-04-27
EP1214938A3 (en) 2003-08-06
EP0573617A1 (en) 1993-12-15
JPH07500085A (ja) 1995-01-05
AU2247592A (en) 1993-01-08

Similar Documents

Publication Publication Date Title
US5856115A (en) Assay for identification therapeutic agents
Barshes et al. Pharmacologic immunosuppression
IE921683A1 (en) Modulation of cellular response to external stimuli
Allison et al. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)
US20130129675A1 (en) Interferon therapies in combination with blockade of stat3 activation
KR100674529B1 (ko) 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물
MXPA06006651A (es) Metodos para suprimir una respuesta inmune o un tratamiento para un trastorno proliferativo.
BG98217A (bg) Определяне на предшественици,метаболизиращи се вчерния дроб до биологично активни продукти и терапевтичното им приложение
WO2016096577A1 (en) Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
CZ212394A3 (en) Enantiomeric hydroxy-xanthine derivatives
MX2007007779A (es) Composiciones para el tratamiento de infeccion de hepatitis c.
KR20070027510A (ko) Ｃｃｉ―７７９ 및 리턱시맵의 항종양성 조합
Hausen et al. Review of immunosuppression for lung transplantation: novel drugs, new uses for conventional immunosuppressants, and alternative strategies
Bielefeldt-Ohmann et al. Potential for interferon-α-based therapy in mesothelioma: assessment in a murine model
EP2091544A2 (fr) Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
Thompson et al. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma
JP2018009011A (ja) ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
Lavon et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation
OH Pharmacology and the use of immunosuppressive agents after hematopoietic cell transplantation
CN113194936A (zh) 含新型化合物和钙调磷酸酶抑制剂的用于预防和治疗移植排斥反应或移植排斥疾病的组合物
Dholakia et al. The use of kinase inhibitors in solid organ transplantation
Lee et al. Lupenone preserves T cell activity by recovery of CD40L expression and protection from cytotoxicity due to methamphetamine exposure
HK40076423A (en) Methods of treating cancer with a sting agonist
KR100954103B1 (ko) 항염증 및 면역억제 효과를 갖는 하이드로퀴논 유도체 화합물 및 이를 함유하는 약학적 조성물
KOYAMA et al. 2. Immunochemotherapy

Legal Events

Date Code Title Description
FC9A Application refused sect. 31(1)